SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug discovery for various indications across different disease areas. They ...

Q2 2025 Management View CEO Christopher C. Gibson emphasized the integration of Exscientia's technology into Recursion OS 2.0, highlighting the company's end-to-end platform capabilities from target ...

The program originated from a joint venture between Rallybio and Recursion focused on discovering and developing novel, orally available small-molecule inhibitors of ENPP1 for HPP patients. Recursion ...

We recently published a list of 8 Best Small-Cap Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...

Following the upgrade, the latest consensus from Recursion Pharmaceuticals' six analysts is for revenues of US$72m in 2023, which would reflect a huge 151% improvement in sales compared to the ...

Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in ...

Recursion also announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-4539, a potential best-in ...